Here is the design of a clinical trial:

Official Title: A Randomized, Open Label, Prospective, Parallel Group Study to Assess the Natural History of COVID-19 and Effects of KB109 in Addition to Supportive Self Care (SSC) Compared to SSC Alone on Measures of Health in Non-hospitalized Patients With Mild-Moderate COVID-19

Included conditions:
- Mild-to-moderate COVID-19

Study Armgroups:
- {'label': 'KB109 + Self Supportive Care (SSC)', 'type': 'OTHER', 'interventionNames': ['Other: KB109 + Self Supportive Care (SSC)']}
- {'label': 'Self Supportive Care (SSC) Alone', 'type': 'OTHER', 'interventionNames': ['Other: Self Supportive Care (SSC) Alone']}

Interventions:
- {'type': 'OTHER', 'name': 'KB109 + Self Supportive Care (SSC)', 'description': 'KB109 is a novel glycan', 'armGroupLabels': ['KB109 + Self Supportive Care (SSC)']}
- {'type': 'OTHER', 'name': 'Self Supportive Care (SSC) Alone', 'description': 'Self Supportive Care (SSC) Alone', 'armGroupLabels': ['Self Supportive Care (SSC) Alone']}

Primary Outcomes:
- {'measure': 'Number of patients experiencing study-product related treatment-emergent adverse events (TEAEs)', 'timeFrame': 'Day 1 to Day 35'}

Please estimate the sample size based on the assumption: 
Not specified in the provided paragraph.
Numbers to be randomised (sample size)
          K031 will enroll approximately 350 to 400 (175â200 patients per group) whereas K032 will enroll approximately 50 patients (25 per group).